It took 15 years and several doctors to reach a diagnosis of NTM lung disease, but today I am living without the assistance of medications.
One of the most frustrating and misunderstood aspects of NTM disease management is the lack of clear correlation between in vitro activity of the drug and the outcome of in vivo treatment.
Attention to safety concerns for patients receiving treatment for NTM lung disease is paramount. Here are some of the steps I take while following patients as they undergo treatment.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.